VNDA - Vanda Pharmaceuticals Reports Third Quarter 2020 Financial Results
Summary:
Q3 2020 Total net product sales of $60.3 million, a 1% increase compared to Q3 2019
Total net product sales for the first nine months of 2020 grew to $180.5 million, a 9% increase compared to the same period in 2019
The HETLIOZ® Smith-Magenis Syndrome marketing authorization applications accepted by the FDA for priority review with a PDUFA-VI target action date of December 1, 2020
#VNDA announced financial and operational results for the third quarter ended September 30, 2020.
Key Financial and Corporate Highlights Third Quarter of 2020
Total net product sales from HETLIOZ® and Fanapt® were $60.3 million in the third quarter of 2020, a 1% increase compared to $59.5 million in the third quarter of 2019. HETLIOZ® net product sales were $39.6 million in the third quarter of 2020, a 5% increase compared to $37.6 million in the third quarter of 2019.
Fanapt® net product sales were $20.7 million in the third quarter of 2020, a 6% decrease compared to $21.9 million in the third quarter of 2019.
Income before taxes was $8.4 million in the third quarter of 2020 compared to $12.3 million in the third quarter of 2019.
See our VNDA AmpCards to learn more.
See VNDA's press release HERE.
#VNDA